Pediatric Clinic, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
Pediatric Neurology, Pediatric University Department, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy.
Acta Biomed. 2022 Mar 21;92(S4):e2021418. doi: 10.23750/abm.v92iS4.12667.
The complex association between neuroinflammation and seizures has been widely investigated in recent years. As mediators of inflammatory response, cytokines like tumor necrosis factor- a (TNF-a) are potential therapeutic targets for epileptic disorders. TNF-a is a pleiotropic cytokine with a controversial role in epileptogenesis, seemingly capable to both favor the genesis of seizures and elicit neuromodulatory responses. Anti-TNF agents are a group of monoclonal antibodies engineered to inhibit the response to this cytokine for antinflammatory purposes. The clinical experience of the use of these drugs in neurological conditions like multiple sclerosis showed controversial results. Evidence in favor of the employment of anti-TNF agents for the treatment of epilepsy are still limited to certain forms of disorders, notably Rasmussen encephalitis, and in carefully selected patients.
近年来，神经炎症与癫痫发作之间的复杂关系受到了广泛的研究。细胞因子如肿瘤坏死因子-α（TNF-α）作为炎症反应的介质，是治疗癫痫疾病的潜在靶点。TNF-α是一种具有多种功能的细胞因子，其在癫痫发生中的作用存在争议，似乎既能促进癫痫发作的发生，又能引发神经调节反应。抗 TNF 药物是一组为了抑制细胞因子反应而设计的单克隆抗体，用于抗炎目的。这些药物在多发性硬化等神经疾病中的临床应用经验显示出了相互矛盾的结果。支持使用抗 TNF 药物治疗癫痫的证据仍然局限于某些形式的疾病，特别是拉森脑炎，并在经过精心挑选的患者中。
